September 5, 2011
Dainippon Sumitomo Pharma (DSP) announced on August 24 that Canadian health authorities have accepted a new drug application (NDA) for its atypical antipsychotic agent lurasidone. Sunovion Pharmaceuticals Canada, a subsidiary of DSP’s US subsidiary Sunovion, applied for the treatment of...read more